Nuo Therapeutics, Inc. (AURX)

Market Cap	62.96M -28.5%
Revenue (ttm)	5.20M +166.6%
Net Income	-2.01M
EPS	-0.04
Shares Out	48.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,100
Open	1.250
Previous Close	n/a
Day's Range	1.250 - 1.300
52-Week Range	0.770 - 3.230
Beta	-800.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Nuo Therapeutics

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: AURX

Financial Performance

In 2025, Nuo Therapeutics's revenue was $3.31 million, an increase of 142.72% compared to the previous year's $1.37 million. Losses were -$2.51 million, 8.11% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 23, 2026

Data Sources Report a data error